Comparative toxicity of known and putative metabolites of 1,3-butadiene in human CD34+ bone marrow cells

Toxicology

Volumn 150, Issue 1-3, 2000, Pages 99-106

  Irons, R D ^a   Pyatt, D W ^a   Stillman, W S ^a   Som, D B ^a   Claffey, D J ^a   Ruth, J A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

1,3 Butadiene; Apoptosis; Colony forming assay; Hematopoietic stem cells

Indexed keywords

1,3 BUTADIENE DERIVATIVE; 3 EPOXYBUTANE 1,2 DIOL; 3,4 EPOXYBUTANE; BUTANE BIS OXIDE; CD34 ANTIGEN; DEXTRO,LEVO BUTANE BIS OXIDE; HYDROQUINONE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; BURST FORMING UNIT E; COLONY FORMING UNIT; COLONY FORMING UNIT GEMM; COLONY FORMING UNIT GM; CONTROLLED STUDY; CYTOTOXICITY; ERYTHROID PRECURSOR CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; METABOLITE; PRIORITY JOURNAL; PROMYELOCYTE; SPECIES DIFFERENCE;

ADULT; ANIMALS; ANTIGENS, CD34; APOPTOSIS; BONE MARROW CELLS; BUTADIENES; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; SPECIES SPECIFICITY;

EID: 0034618670     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(00)00249-3     Document Type: Article

References (36)

1. Asamoto H., Mandel T.E. Thymus in mice bearing the steel mutation. Morphologic studies on fetal, neonatal, organ-cultured, and grafted fetal thymus. Lab. Invest. 45:(5):1981;418-426.
2. Bagby G.C. Jr, Gabourel J.D., Linman J.W. Glucocorticoid therapy in the preleukemic syndrome (Hemopoietic Dysplasia). Ann. Intern. Med. 92:1980;55-58.
3. Bagby G.C. Jr, Lawrence H.J., Neerhout R.C. T-lymphocyte-mediated granulopoietic failure. New Engl. J. Med. 309:1983;1073-1078.
4. Bagby G.C. Jr, Segal G.M., Auerbach A.D., Onega T., Keeble W., Heinrich M.C. Constitutive and induced expression of hematopoietic growth factor genes by fibroblasts from children with Fanconi anemia. Exp. Hematol. 21:1993;1419-1426.
5. Bechtold W.E., Strunk M.R., Chang I.-Y., Ward J.B. Jr, Henderson R.F. Species differences in urinary butadiene metabolites: Comparisons of metabolite ratios between mice, rats, and humans. Toxicol. Appl. Pharmacol. 127:1994;44-49.
6. Berthier R., Douady F., Metral J., Newton I., Schweitzer A., Hollard D. In vitro granulopoiesis in oligoblastic leukaemia: Prognostic value, characterization and serial cloning of bone marrow colony and cluster forming cells in agar culture. Biomedicine. 30:1979;305-311.
7. Chabot B., Stephenson D.A., Chapman V.M., Besmer P., Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature. 335:(1):1988;88-89.
8. Claffey D.J., Ruth J.A. Synthetic route to optically-pure metabolites of butadiene, and their chiral GC separation. Tetrahedron Letts. 37:1996;7929-7932.
9. Cochrane J.E., Skopek T.R. Mutagenicity of butadiene and its epoxide metabolites: I. Mutagenic potential of 1,2-epoxybutene, 1,2,3,4-epoxybutane and 3,4-epoxy-1,2-butanediol in cultured human lymphoblasts. Carcinogenesis. 15:1994;713-717.
10. Colagiovanni D.B., Stillman W.S., Irons R.D. Chemical suppression of a subpopulation of primitive hematopoietic progenitor cells: 1,3-butadiene produces a hematopoietic defect similar to steel or white spotted mutations in mice. Proc. Natl. Acad. Sci. USA. 90:1993;2803-2806.
11. Golde D.W., Cline M.J. Growth of human bone marrow in liquid culture. Blood. 1973:1941;45-57.
12. Golde D.W., Cline M.J. Human preleukemia: Identification of a maturation defect in vitro. New Engl. J. Med. 288:1973;1083-1086.
13. Huff J.E., Melnick R.L., Solleveld H.A., Haseman J.K., Powers M., Miller R.A. Multiple organ carcinogenicity of 1,3-butadiene in B6C3F1 mice after 60 weeks of inhalation exposure. Science. 227:1985;548-549.
14. Irons R.D., Smith C.N., Stillman W.S., Shah R.S., Steinhagen W.H., Leiderman L.J. Macrocytic-megaloblastic anemia in male NIH Swiss mice following repeated exposure to 1,3-butadiene. Toxicol. Appl. Pharmacol. 85:1986a;450-455.
15. Irons R.D., Smith C.N., Stillman W.S., Shah R.S., Steinhagen W.H., Leiderman L.J. Macrocytic-megaloblastic anemia in male B6C3F1 mice following chronic exposure to 1,3-butadiene. Toxicol. Appl. Pharmacol. 83:1986b;95-100.
16. Irons R.D., Cathro H.P., Stillman W.S., Steinhagen W.H., Shah R.S. Susceptibility to 1,3-butadiene-induced leukemogenesis correlates with endogenous ecotropic retroviral background in the mouse. Toxicol. Appl. Pharmacol. 101:1989;170-176.
17. Irons R.D., Stillman W.S., Colagiovanni D.B., Henry V.A. Synergistic action of the benzene metabolite hydroquinone on myelopoietic stimulating activity of granulocyte/macrophage colony-stimulating factor in vitro. Proc. Natl. Acad. Sci. USA. 89:1992;3691-3695.
18. Irons R.D., Le A.T., Som D.B., Stillman W.S. 2′3′-dideoxycytidine-induced thymic lymphoma correlates with species-specific suppression of a subpopulation of primitive hematopoietic progenitor cells in mouse but not rat or human bone marrow. J. Clin. Invest. 95:1995;2777-2782.
19. Irons R.D., Colagiovanni D.B., Stillman W.S. Murine thymic lymphoma is associated with a species-specific hematopoietic progenitor cell subpopulation. Toxicology. 113:1996;59-67.
20. + cell fraction as a measure of hematopoietic stem cells in bone marrow and peripheral blood: Comparison with the CFU-GM assay. Prog. Clin. Biol. Res. 377:1992;513-521.
21. + cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Trans. 19:1997;303-310.
22. Krause D.S., Fackler M.J., Civin C.I., May W.S. CD34: Structure, biology, and clinical utility. Blood. 87:1996;1-13.
23. Leiderman L.J., Stillman W.S., Shah R.S., Steinhagen W.H., Irons R.D. Altered hematopoietic stem cell development in male B6C3F1 mice following exposure to 1,3-butadiene. Exp. Mol. Pathol. 44:1986;50-56.
24. + cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood. 88:1996;3223-3229.
25. Murphy E.D. Effects of mutant steel alleles on leukemogenesis and life-span in the mouse. J. Natl. Cancer Inst. 58:(1):1977;107-109.
26. Neagu C., Hase T. Synthesis of enantiomerically pure 3-butene-1,2-diol derivatives via a sharpless asymmetric epoxidation route. Tetrahedron Letts. 34:(10):1993;1629-1630.
27. Perez H.L., Lahdetie J., Landin H.H., Kilpelainen I., Koivisto P., Peltonen K., Osterman-Golkar S. Haemoglobin adducts of epoxybutanediol from exposure to 1,3-butadiene or butadiene epoxides. Chem. Biol. Interact. 105:1997;181-198.
28. Richert-Boe K.E., Bagby G.C. Jr. In vitro hematopoiesis in myelodysplasia: Liquid and soft-gel culture studies. Hematol./Oncol. Clin. North Am. 6:1992;543-557.
29. Rickert D.E., Baker T.S., Bus J.S., Barrow C.S., Irons R.D. Benzene disposition in the rat after exposure by inhalation. Toxicol. Appl. Pharmacol. 49:1979;417-423.
30. Ruscetti F.W., Boggs D.R., Torok B.J., Boggs S.S. Reduced blood and marrow neutrophils and granulocytic colony-forming cells in Sl/Sld mice. Proc. Soc. Exp. Biol. Med. 152:1976;398-402.
31. Russell E.S. Hereditary anemias of the mouse: a review for geneticists. Adv. Genet. 20:1979;357-411.
32. Segal G.M., Magenis R.E., Brown M., Keeble W., Smith T.D., Heinrich M.C., Bagby G.C. Jr. Repression of Fanconi anemia gene (FACC) expression inhibits growth of hematopoietic progenitor cells. J. Clin. Invest. 94:1994;846-852.
33. +-cells: correlation to the quantitation of circulating haemopoietic progenitor cells by in vitro colony-assay. Br. J. Haematol. 77:1991;453-459.
34. To L.B. Assaying the CFU-GM in blood: correlation between cell dose and haemopoietic reconstitution. Bone Marrow Trans. 5:1990;16-18.
35. Witte O.N. Steel locus defines new multipotent growth factor. Cell. 63:1990;5-6.
36. Zsebo K.M., Williams D.A., Geissler E.N., Broudy V.C., Martin F.H., Atkins H.L., Hsu R.-Y., Birkett N.C., Okino K.H., Murdock D.C., Jacobsen F.W., Langley K.E., Smith K.A., Takeishi T., Cattanach G.M., Galli S.J., Suggs S.V. Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell. 63:(1):1990;213-224.